Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FOXA1 inhibits prostate cancer neuroendocrine differentiation
Jung Kim, Hongjian Jin, Jonathan C. Zhao, et al.
Oncogene (2017) Vol. 36, Iss. 28, pp. 4072-4080
Open Access | Times Cited: 135

Showing 1-25 of 135 citing articles:

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal, Jiaoti Huang, Joshi J. Alumkal, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 24, pp. 2492-2503
Open Access | Times Cited: 643
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Álvaro Quintanal-Villalonga, Joseph M. Chan, Helena A. Yu, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 6, pp. 360-371
Open Access | Times Cited: 399
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Qin Feng, Bin He
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 161
Epigenetic modulations and lineage plasticity in advanced prostate cancer
Rongrong Ge, Zifan Wang, Rodolfo Montironi, et al.
Annals of Oncology (2020) Vol. 31, Iss. 4, pp. 470-479
Open Access | Times Cited: 155
Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies
Nikolas G. Balanis, Katherine M. Sheu, Favour N. Esedebe, et al.
Cancer Cell (2019) Vol. 36, Iss. 1, pp. 17-34.e7
Open Access | Times Cited: 149
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Sylvan C. Baca, David Y. Takeda, Ji-Heui Seo, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 124
Molecular events in neuroendocrine prostate cancer development
Yong Wang, Yu Wang, Xinpei Ci, et al.
Nature Reviews Urology (2021) Vol. 18, Iss. 10, pp. 581-596
Open Access | Times Cited: 122
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
Lina Merkens, Verena Sailer, Davor Lessel, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 86
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis
Mirja Rotinen, Sungyong You, Julie Yang, et al.
Nature Medicine (2018) Vol. 24, Iss. 12, pp. 1887-1898
Open Access | Times Cited: 148
Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression
Bing Song, Su-Hong Park, Jonathan C. Zhao, et al.
Journal of Clinical Investigation (2018) Vol. 129, Iss. 2, pp. 569-582
Open Access | Times Cited: 131
Pioneer of prostate cancer: past, present and the future of FOXA1
Mona Teng, Stanley Zhou, Changmeng Cai, et al.
Protein & Cell (2020) Vol. 12, Iss. 1, pp. 29-38
Open Access | Times Cited: 121
Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Ugo Testa, Germana Castelli, Elvira Pelosi
Medicines (2019) Vol. 6, Iss. 3, pp. 82-82
Open Access | Times Cited: 117
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy
Mitchell G. Lawrence, Daisuke Obinata, Shahneen Sandhu, et al.
European Urology (2018) Vol. 74, Iss. 5, pp. 562-572
Open Access | Times Cited: 103
Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play
Girijesh Kumar Patel, Natasha Chugh, Manisha Tripathi
Cancers (2019) Vol. 11, Iss. 10, pp. 1405-1405
Open Access | Times Cited: 97
The epigenetic and transcriptional landscape of neuroendocrine prostate cancer
Alastair Davies, Amina Zoubeidi, Luke A. Selth
Endocrine Related Cancer (2019) Vol. 27, Iss. 2, pp. R35-R50
Open Access | Times Cited: 77
Cellular rewiring in lethal prostate cancer: the architect of drug resistance
Marc Cárceles-Cordon, William Kevin Kelly, Leonard G. Gomella, et al.
Nature Reviews Urology (2020) Vol. 17, Iss. 5, pp. 292-307
Open Access | Times Cited: 76
Molecular mechanisms underlying the development of neuroendocrine prostate cancer
Shiqin Liu, Busola R. Alabi, Qingqing Yin, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 57-68
Open Access | Times Cited: 44
FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer
Na Liu, Anran Wang, Mengen Xue, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 15
The role of transcription factors in prostate cancer progression
Jongeun Lee, Yoontae Lee
Molecules and Cells (2025), pp. 100193-100193
Open Access | Times Cited: 1
The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
Varune Rohan Ramnarine, Mohammed Alshalalfa, Fan Mo, et al.
GigaScience (2018) Vol. 7, Iss. 6
Open Access | Times Cited: 70
Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance
Yunshin Yeh, Qiaozhi Guo, Zachary M. Connelly, et al.
Advances in experimental medicine and biology (2019), pp. 351-378
Closed Access | Times Cited: 68
Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors
William Hankey, Zhong Chen, Qianben Wang
Cancer Research (2020) Vol. 80, Iss. 12, pp. 2427-2436
Open Access | Times Cited: 67
Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer
Xinpei Ci, Jun Hao, Xin Dong, et al.
Cancer Research (2018) Vol. 78, Iss. 10, pp. 2691-2704
Open Access | Times Cited: 63
Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1
Leiming Wang, Mafei Xu, Chung‐Yang Kao, et al.
Journal of Clinical Investigation (2019) Vol. 130, Iss. 4, pp. 1782-1792
Open Access | Times Cited: 60
Understanding aberrant RNA splicing to facilitate cancer diagnosis and therapy
Xuesen Dong, Ruiqi Chen
Oncogene (2019) Vol. 39, Iss. 11, pp. 2231-2242
Closed Access | Times Cited: 55
Page 1 - Next Page

Scroll to top